CRIS Current Research Information System

GRAMANTIERI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.202
AS - Asia 4.074
EU - Europa 2.867
Continente sconosciuto - Info sul continente non disponibili 271
AF - Africa 221
SA - Sud America 195
OC - Oceania 2
Totale 11.832
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.099
SG - Singapore 1.127
CN - Cina 1.061
IT - Italia 936
VN - Vietnam 860
GB - Regno Unito 418
DE - Germania 276
HK - Hong Kong 272
SE - Svezia 258
FR - Francia 192
NL - Olanda 166
IN - India 163
BR - Brasile 136
KR - Corea 128
RU - Federazione Russa 116
BD - Bangladesh 112
IE - Irlanda 98
JP - Giappone 98
CH - Svizzera 84
FI - Finlandia 77
ZA - Sudafrica 68
UA - Ucraina 61
CA - Canada 59
BG - Bulgaria 43
CI - Costa d'Avorio 41
ID - Indonesia 41
TG - Togo 40
TH - Thailandia 36
SC - Seychelles 33
EE - Estonia 28
PH - Filippine 28
JO - Giordania 23
EC - Ecuador 22
MX - Messico 21
PK - Pakistan 21
PL - Polonia 18
AT - Austria 16
IQ - Iraq 16
TW - Taiwan 16
EU - Europa 15
AR - Argentina 14
TR - Turchia 14
DZ - Algeria 13
BE - Belgio 12
HR - Croazia 10
ES - Italia 9
MK - Macedonia 9
LT - Lituania 8
UZ - Uzbekistan 8
MY - Malesia 7
PE - Perù 7
RO - Romania 7
NG - Nigeria 6
SA - Arabia Saudita 6
CL - Cile 5
CZ - Repubblica Ceca 5
GR - Grecia 5
IL - Israele 5
JM - Giamaica 5
LB - Libano 5
AM - Armenia 4
EG - Egitto 4
HN - Honduras 4
MD - Moldavia 4
PY - Paraguay 4
AZ - Azerbaigian 3
CO - Colombia 3
CR - Costa Rica 3
IR - Iran 3
KZ - Kazakistan 3
MA - Marocco 3
NP - Nepal 3
TN - Tunisia 3
AE - Emirati Arabi Uniti 2
BZ - Belize 2
DK - Danimarca 2
ET - Etiopia 2
GH - Ghana 2
HU - Ungheria 2
PR - Porto Rico 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
SR - Suriname 2
SV - El Salvador 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AU - Australia 1
BO - Bolivia 1
BY - Bielorussia 1
CU - Cuba 1
GE - Georgia 1
GP - Guadalupe 1
GT - Guatemala 1
KE - Kenya 1
KG - Kirghizistan 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LV - Lettonia 1
ML - Mali 1
Totale 11.566
Salva come PNG Salva come JPEG
Città #
Singapore 802
Ashburn 496
Southend 349
Fairfield 302
San Jose 278
Bologna 275
Hefei 272
Hong Kong 248
Chandler 214
Ho Chi Minh City 209
Hanoi 200
Santa Clara 175
Council Bluffs 159
Woodbridge 159
Houston 150
Boardman 139
Wilmington 131
Seattle 129
Beijing 122
Seoul 118
Dublin 98
Princeton 88
Dallas 87
Los Angeles 84
Lauterbourg 80
Milan 80
Ann Arbor 79
Cambridge 79
New York 77
Bern 75
Tokyo 75
Helsinki 61
Da Nang 50
Abidjan 41
Sofia 41
Lomé 40
Dong Ket 35
Jacksonville 35
Westminster 34
Amsterdam 33
Buffalo 33
Johannesburg 32
Nanjing 32
Padova 32
Chicago 31
São Paulo 30
Redondo Beach 28
Rome 28
Florence 27
Haiphong 26
Munich 25
Bengaluru 24
Berlin 24
Amman 23
Frankfurt am Main 22
Jakarta 22
San Diego 22
Montreal 20
Rimini 20
Jinan 19
Saint Petersburg 19
Turin 18
Zhengzhou 18
Guangzhou 17
Hebei 17
Orem 17
Shanghai 16
Bangkok 15
Phoenix 15
Brooklyn 14
Düsseldorf 14
Imola 14
Nuremberg 13
Hải Dương 12
Lahore 12
Nanchang 12
Parma 12
Toronto 12
Brussels 11
Des Moines 11
London 11
Quito 11
Shenzhen 11
Tianjin 11
Denver 10
Jiaxing 10
Naples 10
Philadelphia 10
Pune 10
Shenyang 10
Verona 10
Vienna 10
Warsaw 10
Atlanta 9
Bremen 9
Changsha 9
Chennai 9
Forlì 9
Hangzhou 9
Medford 9
Totale 7.205
Salva come PNG Salva come JPEG
Nome #
Aflatoxin B1 DNA-Adducts in Hepatocellular Carcinoma from a Low Exposure Area 334
Circulating microRNAs, MIR-939, MIR-595, MIR-519d and MIR-494, identify cirrhotic patients with HCC 291
In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3–mediated apoptosis 273
Venom from Cuban Blue Scorpion has tumor activating effect in hepatocellular carcinoma 270
MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma 245
MiR-30e-3p influences tumor phenotype through MDM2/TP53 axis and predicts sorafenib resistance in hepatocellular carcinoma 239
MiR-22/GLUT1 Axis Induces Metabolic Reprogramming and Sorafenib Resistance in Hepatocellular Carcinoma 232
Early CTLA4 increase in CD45+ blood cells: an emerging biomarker of atezolizumab–bevacizumab resistance and worse survival in advanced hepatocarcinoma 228
LncRNAs as novel players in hepatocellular carcinoma recurrence 228
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin 222
Corrigendum: Vidatox 30 CH has tumor activating effect in hepatocellular carcinoma (Scientific Reports (2017) 7 (44685) DOI: 10.1038/srep44685) 218
Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. 206
Molecular and proteomic insight into Notch1 characterization in hepatocellular carcinoma 201
MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer 201
Circulating CD8 lymphocytes predict response to atezolizumab–bevacizumab in hepatocellular carcinoma 192
MicroRNAs at the Crossroad between Immunoediting and Oncogenic Drivers in Hepatocellular Carcinoma 190
Noncoding RNAs in Hepatocellular Carcinoma: Potential Applications in Combined Therapeutic Strategies and Promising Candidates of Treatment Response 189
Different haemodynamic effects of a single dose of long-acting isosorbide-5-mononitrate in healthy subjects and patients with cirrhotic portal hypertension. 185
Direct antiviral treatments for hepatitis c virus have off-target effects of oncologic relevance in hepatocellular carcinoma 185
MiR-199-3p replacement affects E-cadherin expression through Notch1 targeting in hepatocellular carcinoma 182
p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma 179
Hepatic cancer stem cells: Molecular mechanisms, therapeutic implications, and circulating biomarkers 176
MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. 171
MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. 171
GADD45alpha expression in cirrhosis and hepatocellular carcinoma. Relationship with DNA-repair and proliferation. 169
TP53/MicroRNA interplay in hepatocellular carcinoma 169
Improving accuracy in the diagnosis of small HCC (< 20 mm) on cirrhosis by a combined CT-MRI Ultrasound navigation system. Preliminary report of a work in progress. 168
Tissue miRNA 483-3p expression predicts tumor recurrence after surgical resection in histologically advanced hepatocellular carcinomas 168
Oncogenic role of miR-483-3p at the IGF2/483 locus. 165
F.N.27 NOTCH SIGNALLING CONTROLS PROLIFERATION AND SENESCENCE OF HUMAN HEPATOCELLULAR CARCINOMA 164
Animal Models of Hepatocellular Carcinoma: Current Applications in Clinical Research 163
Targeting notch3 in hepatocellular carcinoma: Molecular mechanisms and therapeutic perspectives 161
Notch Signaling and PD-1/PD-L1 Interaction in Hepatocellular Carcinoma: Potentialities of Combined Therapies 160
MiR-122/Cyclin G1 Interaction Modulates p53 Activity and Affects Doxorubicin Sensitivity of Human Hepatocarcinoma Cells. 160
Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. 156
Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions 155
Multifaceted Aspects of Dysfunctional Myelopoiesis in Cancer and Therapeutic Perspectives with Focus on HCC 154
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma (Targeted Oncology, (2020), 15, 6, (773-785), 10.1007/s11523-020-00757-3) 154
Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer. 153
Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study 152
MicroRNAs in Animal Models of HCC 150
MicroRNA as predictive biomarkers of treatment response to tyrosine kinase inhibitors in hepatocellular carcinoma: how much is missing? 145
Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma. 144
MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. 143
Characterization of small nucleolar RNA retaining transcripts in human normal and cancer cells 142
Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma. 139
Brivanib in combination with Notch3 silencing shows potent activity in tumour models 137
T.N.28 P53 IS REGULATED BY NOTCH3 SIGNALLING VIA MDM2 IN HEPATOCELLULAR CARCINOMA 131
Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma 128
MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches 127
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 125
Efficacy of superselective TACE in treatment of HCC 121
MiR-122 targets serpinB3 and is involved in sorafenib resistance in hepatocellular carcinoma 119
Mir-30e-3p/CXCL3 axis is involved in sorafenib resistance of hepatocellular carcinoma through the modulation of the tumor immune microenvironment 118
c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma 117
MicroRNAs as Modulators of Tumor Metabolism, Microenvironment, and Immune Response in Hepatocellular Carcinoma 117
Notch signaling regulation in HCC: From hepatitis virus to non‐coding rnas 115
Low-Baseline PD1+ Granulocytes Predict Responses to Atezolizumab–Bevacizumab in Hepatocellular Carcinoma 115
Notch3 intracellular domain accumulates in HepG2 cell line. 112
Gut microbiome alterations and lenvatinib resistance in hepatocellular carcinoma: the role of Akkermansia muciniphila postbiotics in treatment enhancement 109
miR-30e-3p/CXCL3 axis predicts early tumor escape in sorafenib-treated hepatocellular carcinoma patients. 94
miRNA Signature of Hepatocellular Carcinoma Vascularization: How the Controls Can Influence the Signature 87
Emerging role of microRNAs in the treatment of hepatocellular carcinoma 86
miR-30e-3p/CXCL3 axis predicts early tumor escape in hepatocellular carcinoma patients undergoing sorafenib treatment 82
Animal models of hepatocellular carcinoma prevention 81
MiR-22-3p targets the G2/M checkpoint inhibitor Wee1 and represents a possible biomarker of TACE response in hepatocellular carcinoma 80
Towards precision medicine: a preliminary collection of patient-derived organoids for the screening of personalised therapies in hepatocellular carcinoma 78
MiR-22 downregulation activates HIF-1A pathway and induces tumour progression, metabolic reprogramming and sorafenib resistance in hepatocellular carcinoma 78
null 77
MiR-494 induces metabolic reprogramming through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma 77
The tumour suppressor miR-22 induces metabolic reprogramming through GLUT1 targeting and represents a possible biomarker of Sorafenib response in Hepatocellular Carcinoma 74
Laboratory signs of acute or recent cytomegalovirus infection are common in cirrhosis of the liver 73
CXCL3 is a target of miR-30e-3p and predicts tumor escape in sorafenib-treated HCC patients. 72
miR-30e-3p/CXCL3 axis predicts early tumor escape in sorafenib-treated HCC patients. 70
Pathophysiology roles and translational opportunities of miRNAs in hepatocellular carcinoma 70
MiR-494 induces metabolic reprogramming through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma 64
MiR-22 regulates HIF-1A pathway and tumor progression and represents a possible biomarker of sorafenib response in hepatocellular carcinoma 61
MiR-30e-3p plays a dual role in hepatocellular carcinoma and predicts tumour escape to sorafenib Treatment 56
Circulating microRNAs as biomarkers for stratifying different phases of liver cancer progression and response to therapy 49
Circulating miR-22 Early Predicts TACE Non-Response and Targets WEE1 in Hepatocellular Carcinoma 47
Organic Electrochemical Transistors for Real-Time Detection of Immune System Early Activation during Atezolizumab-Bevacizumab Treatment in Hepatocellular Carcinoma 43
Totale 11.832
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.065
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.065
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022921 0 44 60 86 74 47 19 96 36 84 253 122
2022/20231.084 99 121 62 123 65 93 21 57 192 28 76 147
2023/2024411 32 70 19 37 55 79 13 20 19 30 13 24
2024/20251.731 87 222 141 116 214 55 121 45 44 181 133 372
2025/20265.252 421 427 400 322 455 327 526 243 1.094 359 300 378
2026/2027428 277 151 0 0 0 0 0 0 0 0 0 0
Totale 11.832